The Impact of Menopause: Implications for Mental Health Counselors

2003 ◽  
Vol 25 (4) ◽  
pp. 311-322 ◽  
Author(s):  
Tracy D. Baldo ◽  
Mercedes K. Schneider ◽  
Marty Slyter
Keyword(s):  
Mental Health ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Mental Health Counselors ◽  
The Impact

The purpose of this article is to present a brief, informative view of the impact of menopause along with implications for mental health counselors. Menopause and associated stages are defined; symptoms associated with these stages are discussed; the benefits, risks and consequences of hormone replacement therapy (HRT) are considered; and recommendations for mental health counselors are provided.

Sex Hormone Replacement Therapy in Turner Syndrome: Impact on Morbidity and Mortality

2019 ◽  
Vol 105 (2) ◽  
pp. 468-478 ◽  
Author(s):  
Mette H Viuff ◽  
Agnethe Berglund ◽  
Svend Juul ◽  
Niels H Andersen ◽  
Kirstine Stochholm ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Turner Syndrome ◽  
Hormone Replacement ◽  
Osteoporotic Fractures ◽  
Long Term Effects ◽  
Mortality And Morbidity ◽  
Central Registry ◽  
National Cohort ◽  
The Impact

Abstract Context The long-term effects of female hormone replacement therapy (HRT) in Turner syndrome (TS) are unknown. Objective To examine morbidity, mortality and medicinal use in TS and the impact of HRT in 45,X women. Design and Setting National cohort study, following all TS individuals ever diagnosed in Denmark from 1977 to 2014. Patients and Methods In the Danish Cytogenetic Central Registry, we identified 1156 females diagnosed with TS from 1960 to 2014, and, subsequently, Statistics Denmark randomly identified 115 577 age-matched female controls. TS women and their matched controls were linked with person-level data from the National Patient Registry and the Medication Statistics Registry, and they were compared concerning mortality, hospitalizations, and medical prescriptions. Among 329 45,X women, 44 had never been HRT treated, and 285 had been treated at some point. HRT treated women were compared with untreated concerning mortality, hospitalizations, and medical prescriptions. Results Endocrine and cardiovascular mortality and morbidity were significantly increased in TS compared with the matched controls. Comparing HRT treated with nontreated 45,X women, we found a similar mortality (hazard ratio 0.83, 95% confidence interval 0.38–1.79). Among the HRT-treated 45,X women, we found a significantly lower use of antihypertensives, antidiabetics, and thyroid hormones and significantly reduced hospitalization rates for stroke and osteoporotic fractures. Conclusion Women with TS have an increased overall mortality and morbidity. HRT seems to have a beneficial effect on endocrine conditions, hypertension, and stroke in women with 45,X karyotype, with no clear impact on mortality.

scholarly journals Gatekeeping hormone replacement therapy for transgender patients is dehumanising

2019 ◽  
Vol 45 (7) ◽  
pp. 480-482 ◽  
Author(s):  
Florence Ashley
Keyword(s):  
Mental Health ◽  
Hormone Replacement Therapy ◽  
Informed Consent ◽  
Health Professional ◽  
Replacement Therapy ◽  
Clinical Care ◽  
Hormone Replacement ◽  
Double Standard ◽  
Referral Letter ◽  
Trans People

Although informed consent models for prescribing hormone replacement therapy are becoming increasingly prevalent, many physicians continue to require an assessment and referral letter from a mental health professional prior to prescription. Drawing on personal and communal experience, the author argues that assessment and referral requirements are dehumanising and unethical, foregrounding the ways in which these requirements evidence a mistrust of trans people, suppress the diversity of their experiences and sustain an unjustified double standard in contrast to other forms of clinical care. Physicians should abandon this unethical requirement in favour of an informed consent approach to transgender care.

Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis

2004 ◽  
Vol 22 (6) ◽  
pp. 1045-1054 ◽  
Author(s):  
Katrina Armstrong ◽  
J. Sanford Schwartz ◽  
Thomas Randall ◽  
Stephen C. Rubin ◽  
Barbara Weber
Keyword(s):  
Hormone Replacement Therapy ◽  
Life Expectancy ◽  
Decision Analysis ◽  
Replacement Therapy ◽  
Prophylactic Mastectomy ◽  
Hormone Replacement ◽  
Sensitivity Analyses ◽  
Decision Analytic Model ◽  
Prophylactic Oophorectomy ◽  
The Impact

Purpose The decision about prophylactic oophorectomy is difficult for many premenopausal women with BRCA1/2 mutations because of concerns and controversy about the use of hormone replacement therapy (HRT) after oophorectomy. Patients and Methods A Markov decision analytic model used the most current epidemiologic data to assess the expected outcomes of prophylactic oophorectomy with or without HRT (to age 50 years or for life) in cohorts of women with BRCA1/2 mutations. Sensitivity analyses were conducted to assess the impact of alternative assumptions about effects of HRT, effects of prophylactic oophorectomy, and risks of cancer associated with BRCA1/2 mutations. Results In our model, prophylactic oophorectomy lengthened life expectancy in women with BRCA1/2 mutations, irrespective of whether HRT was used after oophorectomy. This gain ranged from 3.34 to 4.65 years, depending on age at oophorectomy. Use of HRT after oophorectomy was associated with relatively small changes in life expectancy (+0.17 to −0.34 years) when HRT was stopped at age 50, but larger decrements in life expectancy if HRT was continued for life (−0.79 to −1.09 years). HRT was associated with a gain in life expectancy of between 0.39 and 0.79 years for mutation carriers undergoing both prophylactic mastectomy and oophorectomy. Conclusion On the basis of the results of this decision analysis, we recommend that women with BRCA1/2 mutations undergo prophylactic oophorectomy after completion of childbearing, decide about short-term HRT after oophorectomy based largely on quality-of-life issues rather than life expectancy, and, if using HRT, consider discontinuing treatment at the time of expected natural menopause, approximately age 50 years.

Protein metabolism in Turner syndrome and the impact of hormone replacement therapy

2007 ◽  
Vol 67 (3) ◽  
pp. 413-418 ◽  
Author(s):  
Claus Højbjerg Gravholt ◽  
Anne Lene Riis ◽  
Niels Møller ◽  
Jens Sandahl Christiansen
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Turner Syndrome ◽  
Protein Metabolism ◽  
Hormone Replacement ◽  
The Impact

scholarly journals Assessing Quality of Life in Patients with Graves’ Disease Following Thyroidectomy

2019 ◽  
Vol 9 (1) ◽  
pp. 26-30
Author(s):  
S. N. Styazhkina ◽  
A. V. Ledneva ◽  
E. L. Poryvaeva
Keyword(s):  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Surgical Treatment ◽  
Thyroid Gland ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Subtotal Resection ◽  
Graves Disease ◽  
The Impact

Introduction. Graves’ disease is a disorder associated with thyroid gland producing excessive amounts of hormones which causes changes in the functional status of various organs and systems. Among thyroid disorders it takes the second place (after endemic goitre) in prevalence. Until now, there is no consensus on a single strategy for the treatment of disorders of the thyroid gland. This is why this paper aims to assess the impact of surgical treatment of Graves’ disease on patients’ quality of life and whether it would be possible to improve it by following the surgery with hormone replacement therapy.Materials and methods. This paper presents a retrospective analysis of 70 case histories of patients who received surgical treatment for diffuse toxic goitre at the BIH UR “First Republican Teaching Hospital” MH UR,Izhevsk, in the period from 2008 to 2014. Percentages of the disease by stage were as follows: stage II — 20%, stage III — 70%, stage 4 — 10%. One lobe resection was performed in 3% of patients, two lobe resection — in 1%, hemithyroidectomy — in 18±4.6%, subtotal resection — in 8%, thyroidectomy — in 70±5.5%.Results. Percentages of patients with various degrees of severity of postoperative hypothyroidism were as follows: severe — 66%, medium — 29%, light — 5%; there were no Graves’ disease recurrences. Patients’ complaints following thyroidectomy included body weight gain — 79.1±4.8%, cold in extremities — 83.3±4.4%, cardiac arrhythmia — 85.2±4.2%, oedemas — 84.3±4.3%, drowsiness, atonia — 67.1±5.6%, changes in appetite — 21±4.8%, skin pallor — 47.6±5.9%, brittle nails, hair loss — 51.2±5.9%, joint pain — 31.2±5.53%.Conclusion. Hypothyroidism always follows thyroidectomy and requires ongoing hormone replacement therapy with L-thyroxine. Th quality of life does not have to suffer if an individual dosage is established and followed on a permanent basis.

Hormone replacement therapy and the impact of “gap time” in cardiovascular versus breast cancer risk

Maturitas ◽  
2017 ◽  
Vol 100 ◽  
pp. 152 ◽  
Author(s):  
Mihaela Nicoleta Plotogea ◽  
Oana Maria Ionescu ◽  
Elvira Bratila ◽  
Diana Elena Comandasu ◽  
Costin Berceanu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
The Impact ◽  
Gap Time
Sign in / Sign up

Export Citation Format

Share Document